References
[1] Bomback A S, Fervenza F C. Membranous Nephropathy: Approaches to Treatment [J]. Am J Nephrol, 2018, 47 Suppl 1:30-42.
[2] van de Logt A E, Hofstra J M, Wetzels J F. Pharmacological treatment of primary membranous nephropathy in 2016 [J]. Expert Rev ClinPharmacol, 2016, 9(11):1463-1478.
[3] Feng Z, Liu W, Jiang H X, et al. How Does Herbal Medicine Treat Idiopathic Membranous Nephropathy? [J]. Front Pharmacol, 2020, 11:994.
[4] Hoxha E, Stahl R A. Membranous Nephropathy: The Journey Continues ... [J]. EBioMedicine, 2015, 2(5):374-375.
[5] Cai Q, Hendricks A R. Membranous nephropathy: A ten-year journey of discoveries [J]. SeminDiagnPathol, 2020, 37(3): 116-120.
[6] Angioi A, Lepori N, Lopez A C, et al. Treatment of primary membranous nephropathy: where are we now? [J]. J Nephrol, 2018, 31(4):489-502.
[7] Hoxha E, Reinhard L, Castedello T, et al. False positivity for PLA(2)R1 antibody measured by ELISA in a nephrotic patient with no membranous nephropathy [J]. Kidney Int, 2023, 103(2):411-415.
[8] Sethi S, Madden B J, Debiec H, et al. Exostosin 1/Exostosin 2-Associated Membranous Nephropathy [J]. J Am Soc Nephrol, 2019, 30(6):1123-1136.
[9] Custodio F B, Silva C, Helmo F R, et al. Complement System and C4d expression in cases of Membranous nephropathy [J]. J Bras Nefrol, 2017, 39(4):370-375.
[10] Seikrit C, Ronco P, Debiec H. Factor H Autoantibodies and Membranous Nephropathy [J]. N Engl J Med, 2018, 379(25): 2479-2481.
[11] Cravedi P, Jarque M, Angeletti A, et al. Immune-Monitoring Disease Activity in Primary Membranous Nephropathy [J]. Front Med (Lausanne), 2019, 6:241.
[12] Segawa Y, Hisano S, Matsushita M, et al. IgG subclasses and complement pathway in segmental and global membranous nephropathy [J]. PediatrNephrol, 2010, 25(6):1091-1099.
[13] Couser W G, Steinmuller D R, Stilmant M M, et al. Experimental glomerulonephritis in the isolated perfused rat kidney [J]. J Clin Invest, 1978, 62(6):1275-1287.
[14] Chen J S, Chen A, Chang L C, et al. Mouse model of membranous nephropathy induced by cationic bovine serum albumin: antigen dose-response relations and strain differences [J]. Nephrol Dial Transplant, 2004, 19(11):2721-2728.
[15] Kuroki A, Iyoda M, Shibata T, et al. Th2 cytokines increase and stimulate B cells to produce IgG4 in idiopathic membranous nephropathy [J]. Kidney Int, 2005, 68(1):302-310.
[16] Beck L J, Bonegio R G, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy [J]. N Engl J Med, 2009, 361(1):11-21.
[17] Tomas N M, Beck L J, Meyer-Schwesinger C, et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy [J]. N Engl J Med, 2014, 371(24):2277-2287.
[18] Jiang H X, Feng Z, Zhu Z B, et al. Advances of the experimental models of idiopathic membranous nephropathy (Review) [J]. Mol Med Rep, 2020, 21(5):1993-2005.
[19] Zhai R, Jian G, Chen T, et al. Astragalusmembranaceus and Panaxnotoginseng, the Novel Renoprotective Compound, Synergistically Protect against Podocyte Injury in Streptozotocin-Induced Diabetic Rats [J]. J Diabetes Res, 2019:1602892.
[20] Wang W, Cai J, Tang S, et al. Sinomenine Attenuates Angiotensin II-Induced Autophagy via Inhibition of P47-Phox Translo-cation to the Membrane and Influences Reactive Oxygen Species Generation in Podocytes [J]. Kidney Blood Press Res, 2016, 41(2):158-167.
[21] Yang S, Liu M, Chen Y, et al. NaoXinTong Capsules inhibit the development of diabetic nephropathy in db/db mice [J]. Sci Rep, 2018, 8(1):9158.
[22] Zhang L, Yang Z, Zhao Y, et al. Renoprotective effects of GushenJiedu capsule on diabetic nephropathy in rats [J]. Sci Rep, 2020, 10(1):2040.
[23] Fang D, Wan X, Deng W, et al. Fufang XueShuan Tong capsules inhibit renal oxidative stress markers and indices of nephropathy in diabetic rats [J]. Exp Ther Med, 2012, 4(5):871-876.
[24] Wang X H, Lang R, Zeng Q, et al. JianpiQushiHeluo Formula alleviates renal damages in Passive Hemann nephritis in rats by upregulating Parkin-mediated mitochondrial autophagy [J]. Sci Rep, 2021, 11(1):18338.